|
|
Locally advanced and high risk prostate cancer: the best indication for initial radical prostatectomy? |
Hendrik van Poppel
|
Department of Urology, University Hospitals Leuven, Leuven, Belgium |
|
|
Abstract High risk prostate cancer is a deadly disease that needs aggressive treatment.High risk prostate cancer is often treated with androgen deprivation therapy or combined radiohormonotherapy while there is a place for surgery in cases of operable and resectable locally advanced or high risk disease.This review summarizes the results of the different treatment strategies for locally advanced and high risk prostate cancer.Radical prostatectomy monotherapy or in combination with radiotherapy and/or hormonal treatment are analyzed.They show that radical prostatectomy is an effective treatment modality for these tumors.After surgery, the results of the pathology and the follow-up of serum PSA may indicate the need of additional adjuvant or salvage treatment strategies.
|
Received: 01 August 2014
Published: 28 October 2014
|
Corresponding Authors:
Hendrik van Poppel
E-mail: hendrik.vanpoppel@uzleuven.be
|
|
|
[1] |
Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A,Scardino PT, et al. Radical prostatectomy for clinically localized,high risk prostate cancer: critical analysis of risk assessmentmethods. J Urol 2007; 178:493-9.
|
[2] |
Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, FieuwsS, et al. Stratification of high risk prostate cancer into prognosticcategories: a European multi-institutional study. Eur Urol 2014; pii:S0302-2838(14)00071-2. doi: 10.1016/j.eururo.2014.01.020. [Epubahead of print]
|
[3] |
Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, PartinAW. Impact of surgical delay on long-term cancer control forclinically localized prostate cancer. J Urol 2004; 172(5 Pt 1): 1835-9.
|
[4] |
Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG,Scardino PT, et al. Results of radical prostatectomy in men withlocally advanced prostate cancer: multi-institution pooled analysis.Eur Urol 1997; 32: 385-90.
|
[5] |
Joniau S, Hsu CY, Lerut E, Van Baelen A, Haustermans K,Roskams T, et al. A pretreatment table for the prediction of finalhistopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007; 51: 388-96.
|
[6] |
Gallina A, Chun FK, Briganti A, Shariat SF, Montorsi F, SaloniaA, et al. Development and split-sample validation of a nomogrampredicting the probability of seminal vesicle invasion at radicalprostatectomy. Eur Urol 2007; 52: 98-105.
|
[7] |
Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baert L.Accuracy of combined computerized tomography and fine needleaspiration cytology in lymph node staging of localized prostaticcarcinoma. J Urol 1994; 151:1310-4.
|
[8] |
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van derKwast T, et al.EAU Guidelines on prostate cancer. Part 1: Screening,diagnosis, and local treatment with curative intent - Update 2013.Eur Urol 2014; 65:124-37.
|
[9] |
Hsu CY, Joniau S, Van Poppel H. Radical prostatectomy for locallyadvanced prostate cancer: technical aspects of radical prostatectomy.EAU Update Series 2005; 3: 90-7.
|
[10] |
Van Poppel H.Surgery for clinical T3 prostate cancer. Eur UrolSuppl 2005;4:12-4.
|
[11] |
Hsu CY, Joniau S, Roskams T, Oyen R, Van Poppel H. Comparingresults after surgery in patients with clinical unilateral T3a, prostatecancer treated with or without neoadjuvant androgen-deprivationtherapy.BJU Int 2006; 99:311-4.
|
[12] |
Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radicalprostatectomy for clinically advanced (cT3) prostate cancer since theadvent of prostate-specific antigen testing: 15-year outcome. BJU Int2005; 95:751-6.
|
[13] |
Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van deVoorde W, Baert L.Radical prostatectomy can provide a cure forwell-selected clinical stage T3 prostate cancer.Eur Urol 2000; 38:372-9.
|
[14] |
Briganti A, Karakiewicz PI, Chun FK, Gallina A, Salonia A, ZanniG, et al. Percentage of positive biopsy cores can improve the abilityto predict lymph node invasion in patients undergoing radicalprostatectomy and extended pelvic lymph node dissection. Eur Urol2007; 51:1573-81.
|
[15] |
Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J,Montironi R, et al. Radical prostatectomy for locally advancedprostate cancer: results of a feasibility study (EORTC 30001). Eur JCancer 2006; 42:1062-7.
|
[16] |
van den Ouden D, Hop WC, Schroder FH. Progression in andsurvival of patients with locally advanced prostate cancer (T3)treated with radical prostatectomy as monotherapy. J Urol 1998;160: 1392-7.
|
[17] |
Isorna Martínez de la Riva S, Belón López-Tomasety J, MarreroDomínguez R, Alvarez Cruz E, Santamaría Blanco P. Radicalprostatectomy as monotherapy for locally advanced prostate cancer(T3a): 12 years follow-up. Arch Esp Urol 2004; 57: 679-92.
|
[18] |
Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H.Outcome ofsurgery for clinical unilateral T3a prostate cancer: a single-institutionexperience.Eur Urol 2007; 51:121-9.
|
[19] |
Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, KocjancicE, et al. Is radical prostatectomy feasible in all cases of locallyadvanced non-bone metastatic prostate cancer? Results of a singleinstitutionstudy. Eur Urol 2007; 51:922-30.
|
[20] |
Lange PH. Is surgery good for advanced localised prostate cancer?It's time to find out! Eur Urol 2007; 51:873-5.
|
[21] |
Bolla M, Van Poppel H, Collette L, van Cangh P, Vekemans K, DaPozzo L, et al. European Organization for Research and Treatmentof Cancer. Postoperative radiotherapy after radical prostatectomy: arandomised controlled trial (EORTC trial 22911). Lancet 2012; 380:2018-27.
|
[22] |
Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G,Troyer D, et al. Adjuvant radiotherapy for pathologically advancedprostate cancer: a randomised clinical trial.JAMA 2006;296: 2329-35.
|
[23] |
Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, Kaouk J, etal. Radical prostatectomy as primary treatment modality for locallyadvanced prostate cancer: a prospective analysis. Urology 2006; 67:1253-6.
|
[24] |
Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-termoutcome following radical prostatectomy in men with clinical stageT3 prostate cancer. J Urol 2006; 176: 564-8.
|
[25] |
Freedland SJ, Partin AW, Humphreys EB, Mangold LA, WalshPC. Radical prostatectomy for clinical stage T3a disease.Cancer2007;109: 1273-8.
|
[26] |
Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-termpotency, continence, and survival outcomes of radical prostatectomyfor clinically high-risk or locally advanced prostate cancer.Urology2007; 69:1170-5.
|
[27] |
Secin FP, Bianco FJ Jr, Vickers AJ, Reuter V, Wheeler T, Fearn PA,et al. Cancer-specific survival and predictors of prostate-specificantigen recurrence and survival in patients with seminal vesicleinvasion after radical prostatectomy. Cancer 2006; 106: 2369-75.
|
[28] |
Masterson TA, Pettus JA, Middleton RG, Stephenson RA. Isolatedseminal vesicle invasion imparts better outcomes after radicalretropubic prostatectomy for clinically localized prostate cancer:prognostic stratification of pt3b disease by nodal and margin status.Urology 2005; 66: 152-5.
|
[29] |
Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radicalprostatectomy for clinical T4 prostate cancer. Cancer 2006; 106:2603-9.
|
[30] |
Donohue JF, Bianco FJ Jr, Kuroiwa K, Vickers AJ, Wheeler TM,Scardino PT, et al. Poorly differentiated prostate cancer treatedwith radical prostatectomy: long-term outcome and incidence ofpathological downgrading. J Urol 2006; 176: 991-5.
|
[31] |
Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS.Outcome after radical prostatectomy with a pretreatment prostatebiopsy Gleason score of ≥ 8. BJU Int 2003; 92: 539-44.
|
[32] |
Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.Predicting recurrence after radical prostatectomy for patients withhigh risk prostate cancer. J Urol 2003; 169: 157-63.
|
[33] |
Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ,Amling CL, et al. Clinical and pathologic outcome after radicalprostatectomy for prostate cancer patients with a preoperativeGleason sum of 8 to 10. Cancer 2006; 107: 1265-72.
|
[34] |
Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radicalprostatectomy for pathological Gleason 8 or greater prostate cancer:influence of concomitant pathological variables. J Urol 2002; 167:117-22.
|
[35] |
Oefelein MG, Grayhack JT, McVary KT. Survival after radicalretropubic prostatectomy of men with clinically localized high gradecarcinoma of the prostate. Cancer 1995; 76: 2535-42.
|
[36] |
Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sake W, Grignon D,et al. Role of radical prostatectomy in patients with prostate cancerof high Gleason score. Prostate 1999; 39: 60-6.
|
[37] |
Mian BM, Troncoso P, Okiharan K, Bhadkamkar V, Johnston D,Reyes AO, et al. Outcome of patients with Gleason score 8 or higherprostate cancer following radical prostatectomy alone. J Urol 2002;167: 1675-80.
|
[38] |
Serni S, Masieri L, Minervini A, Lapini A, Nesi G, Carini M. Cancerprogression after anterograde radical prostatectomy for pathologicGleason score 8 to 10 and influence of concomitant variables.Urology 2006; 67: 373-8.
|
[39] |
Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC,Locally advanced and high risk prostate cancer Scardino PT. Can radical prostatectomy alter the progression ofpoorly differentiated prostate cancer? J Urol 1994; 152: 1843-9.
|
[40] |
Perrotti M, Rabbani F, Russo P, Solomon MC, Fair WR. Earlyprostate cancer detection and potential for surgical cure in men withpoorly differentiated tumors. Urology 1998; 52: 106-10.
|
[41] |
Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R,Malkowicz SB, et al. Radical prostatectomy for high-grade prostatecancer. Urology 2006; 68: 367-70.
|
[42] |
Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, NanusD, Menon M. Long-term survival in men with high grade prostatecancer: a comparison between conservative treatment, radiationtherapy and radical prostatectomy—a propensity scoring approach. JUrol 2007; 177: 911-5.
|
[43] |
Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, et al.Comparative effectiveness of radical prostatectomy and radiotherapyin prostate cancer: observational study of mortality outcomes. BMJ2014; 348: g1502. doi: 10.1136/bmj.g1502.
|
[44] |
Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma ofthe prostate: a comparison of current local therapies. Urology 2001;57: 1121-6.
|
[45] |
Kibel AS, Nelson JB. Adjuvant and salvage treatment optionsfor patients with high-risk prostate cancer treated with radicalprostatectomy.Prostate Cancer Prostatic Dis 2007; 10: 119-26.
|
[1] |
S. Sfanos Karen,Yegnasubramanian Srinivasan,G. Nelson William,L. Lotan Tamara,Kulac Ibrahim,L. Hicks Jessica,Zheng Qizhi,J. Bieberich Charles,C. Haffner Michael,M. De Marzo Angelo. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease[J]. Asian Journal of Urology, 2019, 6(1): 10-25. |
[2] |
Dong Liang,C. Zieren Richard,Xue Wei,M. de Reijke Theo,J. Pienta Kenneth. Metastatic prostate cancer remains incurable, why?[J]. Asian Journal of Urology, 2019, 6(1): 26-41. |
[3] |
M. Armstrong Cameron,C. Gao Allen. Current strategies for targeting the activity of androgen receptor variants[J]. Asian Journal of Urology, 2019, 6(1): 42-49. |
[4] |
B. Isaacs William,Xu Jianfeng. Current progress and questions in germline genetics of prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 3-9. |
[5] |
Etheridge Tyler,Damodaran Shivashankar,Schultz Adam,A. Richards Kyle,Gawdzik Joseph,Yang Bing,Cryns Vincent,F. Jarrard David. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier[J]. Asian Journal of Urology, 2019, 6(1): 57-64. |
[6] |
Chia-Yi Chu Gina,W.K. Chung Leland,Gururajan Murali,Hsieh Chia-Ling,Josson Sajni,Nandana Srinivas,Sung Shian-Ying,Wang Ruoxiang,Boyang Wu Jason,E. Zhau Haiyen. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics[J]. Asian Journal of Urology, 2019, 6(1): 65-81. |
[7] |
Dicken Haley,J. Hensley Patrick,Kyprianou Natasha. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled[J]. Asian Journal of Urology, 2019, 6(1): 82-90. |
[8] |
Xu Lingfan,Chen Junyi,Liu Weipeng,Liang Chaozhao,Hu Hailiang,Huang Jiaoti. Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 91-98. |
[9] |
Chen Kenneth,Jack Tay Kae,Mee Law Yan,Aydin Hakan,Ho Henry,Cheng Christopher,Shyi Peng Yuen John. Outcomes of combination MRI-targeted and transperineal template biopsy in restaging low-risk prostate cancer for active surveillance[J]. Asian Journal of Urology, 2018, 5(3): 184-193. |
[10] |
Chen Shulian,Gao Rang,Li Hong,Wang Kunjie. Management of acquired rectourethral fistulas in adults[J]. Asian Journal of Urology, 2018, 5(3): 149-154. |
[11] |
Chen Kenneth,Sim Allen,Kan Alex Ford. The effect of adjunct caudal block on postoperative analgesia in robot-assisted laparoscopic radical prostatectomy: A prospective randomized controlled, single blinded pilot study in a tertiary centre[J]. Asian Journal of Urology, 2018, 5(2): 122-126. |
[12] |
Su Jiarui,Jonathan Aslim Edwin,Aydin Hakan,HoonTan Puay,Sun SienHo Henry. A rare case of isolated castrate resistant bilateral testicular metastases in advanced prostate cancer[J]. Asian Journal of Urology, 2018, 5(2): 127-130. |
[13] |
Per-Anders Abrahamsson. Intermittent androgen deprivation therapy in patients with prostate cancer:Connecting the dots[J]. Asian Journal of Urology, 2017, 4(4): 208-222. |
[14] |
Yoshiyasu Amiya, Yasutaka Yamada, Masahiro Sugiura, Makoto Sasaki, Takayuki Shima, Noriyuki Suzuki, Hiroomi Nakatsu, Shino Murakami, Jun Shimazaki. Outcomes of patients older than 75 years with non-metastatic prostate cancer[J]. Asian Journal of Urology, 2017, 4(2): 102-106. |
[15] |
Dingwei Ye, Yiran Huang, Fangjian Zhou, Keji Xie, Vsevolod Matveev, Changling Li, Boris Alexeev, Ye Tian, Mingxing Qiu, Hanzhong Li, Tie Zhou, Peter De Porre, Margaret Yu, Vahid Naini, Hongchuan Liang, Zhuli Wu, Yinghao Sun. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia[J]. Asian Journal of Urology, 2017, 4(2): 75-85. |
|
|
|
|